Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system (CNS) products. More than 30 posters, including a late-breaking presentation on data from the pivotal Phase III trial of oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS), will be unveiled at the 63rd American Academy of Neurology Annual Meeting in Honolulu, HI, April 9-16, 2011.

Featured presentations include:

• Data from the Phase III ALLEGRO trial evaluating oral laquinimod in the treatment of RRMS, scheduled for presentation during the Late-Breaking Science Clinical Trials Session.
• Preliminary analysis of the Coptimize study, assessing disease course and quality of life outcomes of patients switching to Copaxone^® (glatiramer acetate injection) from other approved injectable and infused disease modifying therapies for RRMS. Additional data from the QualiCop study demonstrating the effects of Copaxone^® treatment on progression of disability, cognition and fatigue and the impact of these factors on compliance and adherence.
• Data demonstrating remyelination, motor neuron preservation and a neuroprotective effect of COPAXONE^® in experimental autoimmune encephalomyelitis (EAE).
• New preclinical data providing evidence that the novel mechanism of action (MOA) of oral laquinimod addresses the irreversible pathological processes of MS by reducing axonal damage and neurodegeneration.
• A retrospective analysis of IMS Longitudinal Prescription data demonstrating that rasagiline is associated with significantly higher compliance and persistence rates than other antiparkinson therapies.

Platform Presentations/Poster Sessions:

AZILECT^®

• [IN10-1.002] Assessing the Occurrence of Serotonin Toxicity in Parkinson's Disease Patients Receiving Rasagiline and Antidepressants (Integrated Neuroscience Poster Session: Treatment of Movement Disorders, April 14, 2011 at 2:30 PM HAST) Michel Panisset, Jack J. Chen, Sean H. Rhyee
• [P05.100] Parkinson's Disease Drug Therapies: Medication Compliance and Persistence Update (Session P05: Movement Disorders: Parkinson's Disease: Treatment, April 13, 2011 at 2:00 PM HAST) Marcy L. Tarrants, Jennifer Millard, Dongmu Zhang, Sarah Rudolph, Adam Foote, Jane Castelli-Haley

COPAXONE^®

• [P04.193] Insights from the Coptimize Study: Characteristics of Relapsing Remitting Multiple Sclerosis (RRMS) Patients Switching to Glatiramer Acetate (Session P04: Multiple Sclerosis: Interventions II, April 13, 2011 at 7:30 AM HAST) Tjalf Ziemssen, Adriana Carra, Nina Del Klippel, Joao de Sa, Jette Frederiksen, Olivier Heinzlef, Clementine Karageorgiou, Krisztina Kovacs, Anne-Marie Landtblom, Lubomir Lisy, Ovidiu Bajenaru, Chin-Piao Tsai, Niall Tubridy, Galina Vorobeychik
• [PD6.006] Results from the 5-Year Prospective Follow-Up of Patients Receiving Glatiramer Acetate in the PreCISe Study on Delaying Conversion to CDMS (Poster Discussion VI: Multiple Sclerosis: Interventions III, April 14, 2011 at 2:00 PM HAST) Vittorio Martinelli, Giancarlo Comi, Mariaemma Rodegher, Lucia Moiola, Ovidiu Bajenaru, Adriana Carra, Irina Elovaara, Franz Fazekas, Hans Hartung, Jan Hillert, John King, Samuel Komoly, Catherine Lubetzki, Xavier Montalban, Kjell Morten Myhr, Mads Ravnborg, Peter Rieckmann, Daniel Wynn, Carolyn Young, Massimo Filippi
• [P07.157] Monitoring QoL, Fatigue, and Cognition in RRMS Patients during Treatment with Glatiramer Acetate (Session P07: Multiple Sclerosis: Functional Outcomes, April 14, 2011 at 2:00 PM HAST) Tjalf Ziemssen, Iris Katharina Penner, Josef H. Hoffmann, Pasquale Calabrese
• [P05.024] Remyelination and Preservation of Motor Neurons by Glatiramer Acetate Treatment in Mice with Experimental Autoimmune Encephalomyelitis (Session P05: Multiple Sclerosis: Models, April 13, 2011 at 2:00 PM HAST) Rina Aharoni, Anya Vainshtein, Vera Shinder, Ariel Stock, Raya Eilam, Ruth Arnon
• [P05.023] The Combined Treatment of Glatiramer Acetate (GA) and Salirasib Attenuates Experimental Autoimmune Encephalomyelitis (EAE) (Session P05: Multiple Sclerosis: Models, April 13, 2011 at 2:00 PM HAST) Elizabeta Aizman, Joab Chapman, Adi Mor, Yaniv Assaf, Yoel Kloog

Laquinimod

• The Assessment of Oral Laquinimod in Preventing Progression of RRMS (ALLEGRO): Efficacy and Safety Results (Late-Breaking Science Clinical Trials Session, April 15, 2011 at 12:00 PM HAST) Giancarlo Comi
• [P05.030] Effect of Laquinimod on Cuprizone-Induced Demyelination in Mice (Session P05: Multiple Sclerosis: Models, April 13, 2011 at 2:00 PM HAST) Wolfgang Brück, Ramona Pförtner, Christiane Wegner
• [P02.170] Laquinimod Skews Monocytes to a Regulatory Phenotype and Modulates Autoimmune Demyelination Via Brain Derived Neurotrophic Factor (Session P02: Multiple Sclerosis: Immunology I, April 12, 2011 at 7:30 AM HAST) Jan Thöne, De-Hyung Lee, Gisa Ellrichmann, Liat Hayardeny, Ralf Linker, Ralf Gold

Source: Teva Pharmaceutical Industries Ltd.